Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologiaFeb 11, 2025

New Approaches to Non-Dialysis Treatment in Chronic Kidney Disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

Chronic kidney disease (CKD) is increasingly affecting individuals globally, driven by factors such as aging, obesity, diabetes, and hypertension.

Combination therapy using a Renin-Angiotensin-Aldosterone System inhibitor and a sodium-glucose cotransporter-2 inhibitor may slow CKD progression.
Updated guidelines recommend a tailored, multi-drug approach to manage residual cardiorenal risk in patients.
First-line therapies for diabetes mellitus and CKD include RAAS inhibitors and SGLT-2 inhibitors, according to KDIGO guidelines.
Additional agents like GLP-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists may provide further cardiorenal protection.
Endothelin Receptor Antagonists have shown potential benefits in reducing protein levels in urine and protecting kidney function.

Simplified

Chronic kidney disease (CKD) is an increasingly prevalent pathological condition. The global rise in the number of individuals affected by CKD is dependent on the ageing, as well as on the growing prevalence of obesity, diabetes and hypertension. The need for treatment strategies aimed at preventing the onset of CKD and slowing its progression has led to the implementation of combination therapy, consisting of a Renin-Angiotensin-Aldosterone System inhibitor (RAASi) and a sodium-glucose cotransporter-2 inhibitor (SGLT-2i), which has demonstrated efficacy in slowing CKD progression and reducing the occurrence of cardiovascular events. Updated guidelines recommend a tailored, multi-drug approach based on the residual cardiorenal risk of the individual patient. The KDIGO guidelines advocate for a stepwise approach in managing diabetes mellitus and CKD, with RAASi and SGLT-2i as first-line therapy, and GLP-1 receptor agonists (GLP-1 RA) and non-steroidal mineralocorticoid receptor antagonists (MRAs) as additional agents for further cardiorenal protection. Endothelin Receptor Antagonists (ERAs), a newer class of drugs, have shown antiproteinuric and nephroprotective effects in various trials. The objective of developing increasingly effective and personalized therapeutic strategies underscores the need to combine multiple drug classes that can act synergistically on different pathways.

New Approaches to Non-Dialysis Treatment in Chronic Kidney Disease

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief